RET and metastatic neoplasm: The study of Signorini and coworkers reporting a ten-year clinical update of a large RET Gly533Cys fMTC kindred indicates a large clinical variability, ranging from only elevated calcitonin level (3%) to local metastatic disease (25%); 42% of the individuals were cured and the majority (56%) had stable chronic disease (12).